1. Infection

Infection

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-169847
    ZK-806450 247188-27-8 98%
    ZK-806450 is a compound with antiviral activity. ZK-806450 has a high binding potential to the allosteric binding site of the SARS-CoV-2 3CL protease. ZK-806450 can also specifically and stably bind to the GAG site of the dengue virus envelope protein.
    ZK-806450
  • HY-169932
    APOL1-IN-2 2956781-84-1 98%
    APOL1-IN-2 (Compound 467) is the inhibitor for Apolipoprotein 1 (APOL1). APOL1-IN-2 reduces the APOL1 G2/G1 induced cell death in HEK293 with EC50 of 4.74 nM and 14.3 nM. APOL1-IN-2 reduces the APOL1 G2/G1/G0 induced death of trypanosomes with EC50 of 2.24, 6.03 and 3.72 nM, respectively.
    APOL1-IN-2
  • HY-169965
    Succinate dehydrogenase-IN-4 98%
    Succinate dehydrogenase-IN-4 (Compound 4b) is the inhibitor for succinate dehydrogenase with an IC50 of 3.38 μM. Succinate dehydrogenase-IN-4 exhibits antifungal activity against Physalospora piricola and Colletotrichum orbiculare with EC50 of 16.33 μM and 18.06 μM.
    Succinate dehydrogenase-IN-4
  • HY-169977
    CKP-25 98%
    CKP-25 is an inhibitor for the interaction between Spike RBD-ACE2, that prevents the virus from entering the host cell, thereby reducing the replication and virus infection. CKP-25 inhibits SARS-CoV-2 with IC50 of 3.5 μM in Vero E6 cell.
    CKP-25
  • HY-169997
    LU9 98%
    LU9 is a potent 3CLpro inhibitor with an IC50 value of 0.34 µM. LU9 has the potential for the research of SARS-CoV-2.
    LU9
  • HY-17003R
    Saquinavir mesylate (Standard) 149845-06-7 98%
    Saquinavir mesylate (Standard) (Ro 31-8959/003 (Standard)) is the analytical standard of Saquinavir mesylate (HY-17003). This product is intended for research and analytical applications. Saquinavir (Ro 31-8959) mesylate is an orally active HIV protease inhibitor that can be used in the research of AIDS. Saquinavir mesylate also has anti-inflammatory activity and can induce apoptosis of human red blood cells.
    Saquinavir mesylate (Standard)
  • HY-17007S
    Saquinavir-d9 1356355-11-7 98%
    Saquinavir-d9 (Ro 31-8959-d9) is the deuterium labeled Saquinavir (HY-17007). Saquinavir (Ro 31-8959) is an orally active HIV protease inhibitor that can be used in the research of AIDS. Saquinavir also has anti-inflammatory activity and can induce apoptosis of human red blood cells.
    Saquinavir-d9
  • HY-17010R
    Retapamulin (Standard) 224452-66-8
    Retapamulin (Standard) is the analytical standard of Retapamulin. This product is intended for research and analytical applications. Retapamulin (SB-275833) is a topical antibiotic that binds Staphylococcus aureus and E. coli ribosomes with a Kd of 3 nM. Retapamulin can be used in researches of atopic dermatitis and prostate cancer[1][2][8].
    Retapamulin (Standard)
  • HY-17016R
    Oseltamivir phosphate (Standard) 204255-11-8 98%
    Oseltamivir (phosphate) (Standard) is the analytical standard of Oseltamivir (phosphate). This product is intended for research and analytical applications. Oseltamivir phosphate (GS 4104) is a neuraminidase inhibitor recommended for the treatment and prophylaxis of influenza A and B.
    Oseltamivir phosphate (Standard)
  • HY-17016S
    Oseltamivir-d5 phosphate 2815520-86-4 98%
    Oseltamivir-d5 (phosphate) is the deuterium labeled Oseltamivir phosphate. Oseltamivir phosphate (GS 4104) is a neuraminidase inhibitor recommended for the treatment and prophylaxis of influenza A and B.
    Oseltamivir-d5 phosphate
  • HY-17028A
    (Rac)-Besifloxacin hydrochloride 1398566-43-2 98%
    (Rac)-Besifloxacin Hydrochloride is a fourth generation fluoroquinolone antibiotic. (Rac)-Besifloxacin Hydrochloride is a DNA gyrase and topoisomerase IV inhibitor. (Rac)-Besifloxacin Hydrochloride has broad-spectrum antibacterial activity, it is effective against Gram-negative and Gram-positive aerobic and anaerobic strains and reduces the incidence of drug resistance. (Rac)-Besifloxacin Hydrochloride has anti-inflammatory activity. Besifloxacin Hydrochloride can be used in bacterial conjunctivitis research.
    (Rac)-Besifloxacin hydrochloride
  • HY-17029R
    Epothilone B (Standard) 152044-54-7 98%
    Epothilone B (Standard) is the analytical standard of Epothilone B. This product is intended for research and analytical applications. Epothilone B is a microtubule stabilizer with a Ki of 0.71μM. It acts by binding to the αβ-tubulin heterodimer subunit which causes decreasing of αβ-tubulin dissociation.
    Epothilone B (Standard)
  • HY-170309
    NZ-804 2858658-44-1 98%
    NZ-804 is an orally active inhibitor for SARS-CoV-2 main protease Mpro with an IC50 of 8.9 nM. NZ-804 inhibits the SARS-CoV-2 replication in HeLa-hACE2 cell with an EC50 of 14 nM. NZ-804 exhibits board-spectrum antiviral activity aganst multiple CoVs. NZ-804 diminishes virus replication in mouse and hamster model.
    NZ-804
  • HY-170357
    SARS-CoV-2 3CLpro-IN-28 2603242-35-7 98%
    SARS-CoV-2 3CLpro-IN-28 (Compound 19) is an inhibitor for SARS-CoV-2 3CLpro with an IC50 of 0.018 μM.
    SARS-CoV-2 3CLpro-IN-28
  • HY-170358
    Antileishmanial agent-31 861382-34-5 98%
    Antileishmanial agent-31 (Compound p1) is a pyrazole derivative. Antileishmanial agent-31 has anti-leishmania activity with an IC50 of 35.53 μg/mL. In addition, Antileishmanial agent-31 has high stability. Antileishmanial agent-31 can be used for anti-leishmaniasis research.
    Antileishmanial agent-31
  • HY-170386
    TXY541 1499168-63-6 98%
    TXY541 is an orally active antibacterial agent that can be converted to PC190723 (HY-146331) under physiological conditions. TXY541 has good antibacterial effect against Staphylococcus aureus and low toxicity to mammalian cells.
    TXY541
  • HY-17041R
    Darunavir Ethanolate (Standard) 635728-49-3 98%
    Darunavir (Ethanolate) (Standard) is the analytical standard of Darunavir (Ethanolate). This product is intended for research and analytical applications. Darunavir ethanolate (TMC114 Ethanolate) is a potent HIV protease inhibitor used to treat and prevent HIV/AIDS. Darunavir has a Ki of 1 nM for wild type HIV-1 protease.
    Darunavir Ethanolate (Standard)
  • HY-170431
    SAL-0010042 521298-46-4 98%
    SAL-0010042 is the inhibitor for Plasmodium phosphodiesterase β (PDEβ), that inhibits the hydrolysis of cAMP and cGMP (IC50=48.9 nM) in gametocytes, activates PKG, and inhibits the growth and development of Plasmodium (IC50 for 3D7 and Dd2 is 142 nM and 218 nM). SAL-0010042 inhibits hPDE5 and hPDE6 with IC50 of 632 nM and 73 nM.
    SAL-0010042
  • HY-170440
    ATV2301 3049172-60-0 98%
    ATV2301 is an orally active anti-influenza agent (EC50, H1N1 = 1.88 nM, H3N2 = 4.77 nM). ATV2301’s anti-influenza activity is due to its effects on polymerase acid protein (PA), nuclear protein (NP), and RNA-dependent RNA polymerase (RdRp).
    ATV2301
  • HY-170483
    Antitumor agent-191 98%
    Antitumor agent-191 (Compound 7) exhibits antiviral activity against HSV-1 and HIV with EC50 of 0.03 μM and 0.81 μM. Antitumor agent-191 exhibits potential antitumor efficacy, that inhibits cancer cell HepG2, WI-38, Vero and MCF-7, with IC50s of 19.6, 39.3, 18.3 and 28 μM, respectively.
    Antitumor agent-191
Cat. No. Product Name / Synonyms Application Reactivity